Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial. / Razquin, Cristina; Toledo, Estefanía; Clish, Clary B.; Ruiz-Canela, Miguel; Dennis, Courtney; Corella, Dolores; Papandreou, Christopher; Ros, Emilio; Estruch, Ramon; Guasch-Ferré, Marta; Gómez-Gracia, Enrique; Fitó, Montserrat; Yu, Edward; Lapetra, José; Wang, Dong; Romaguera, Dora; Liang, Liming; Alonso-Gómez, Angel; Deik, Amy; Bullo, Mónica; Serra-Majem, Lluis; Salas-Salvadó, Jordi; Hu, Frank B.; Martínez-González, Miguel A.
In: Diabetes Care, Vol. 41, No. 12, 2018, p. 2617-2624.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial
AU - Razquin, Cristina
AU - Toledo, Estefanía
AU - Clish, Clary B.
AU - Ruiz-Canela, Miguel
AU - Dennis, Courtney
AU - Corella, Dolores
AU - Papandreou, Christopher
AU - Ros, Emilio
AU - Estruch, Ramon
AU - Guasch-Ferré, Marta
AU - Gómez-Gracia, Enrique
AU - Fitó, Montserrat
AU - Yu, Edward
AU - Lapetra, José
AU - Wang, Dong
AU - Romaguera, Dora
AU - Liang, Liming
AU - Alonso-Gómez, Angel
AU - Deik, Amy
AU - Bullo, Mónica
AU - Serra-Majem, Lluis
AU - Salas-Salvadó, Jordi
AU - Hu, Frank B.
AU - Martínez-González, Miguel A.
N1 - Publisher Copyright: © 2018 by the American Diabetes Association.
PY - 2018
Y1 - 2018
N2 - OBJECTIVE Specific lipid molecular changes leading to type 2 diabetes (T2D) are largely unknown. We assessed lipidome factors associated with future occurrence of T2D in a population at high cardiovascular risk. RESEARCH DESIGN AND METHODS We conducted a case-cohort study nested within the PREDIMED trial, with 250 incident T2D cases diagnosed during 3.8 years of median follow-up, and a random sample of 692 participants (639 noncases and 53 overlapping cases) without T2D at baseline. We repeatedly measured 207 plasma known lipid metabolites at baseline and after 1 year of follow-up. We built combined factors of lipid species using principal component analysis and assessed the association between these lipid factors (or their 1-year changes) and T2D incidence. RESULTS Baseline lysophosphatidylcholines and lysophosphatidylethanolamines (lyso-phospholipids [LPs]), phosphatidylcholine-plasmalogens (PC-PLs), sphingomyelins (SMs), and cholesterol esters (CEs) were inversely associated with risk of T2D (multivariable-adjusted P for linear trend £0.001 for all). Baseline triacylglycerols (TAGs), diacylglycerols (DAGs), and phosphatidylethanolamines (PEs) were positively associated with T2D risk (multivariable-adjusted P for linear trend <0.001 for all). One-year changes in these lipids showed associations in similar directions but were not significant after adjustment for baseline levels. TAGs with odd-chain fatty acids showed inverse associations with T2D after adjusting for total TAGs. CONCLUSIONS Two plasma lipid profiles made up of different lipid classes were found to be associated with T2D in participants at high cardiovascular risk. A profile including LPs, PC-PLs, SMs, and CEs was associated with lower T2D risk. Another profile composed of TAGs, DAGs, and PEs was associated with higher T2D risk.
AB - OBJECTIVE Specific lipid molecular changes leading to type 2 diabetes (T2D) are largely unknown. We assessed lipidome factors associated with future occurrence of T2D in a population at high cardiovascular risk. RESEARCH DESIGN AND METHODS We conducted a case-cohort study nested within the PREDIMED trial, with 250 incident T2D cases diagnosed during 3.8 years of median follow-up, and a random sample of 692 participants (639 noncases and 53 overlapping cases) without T2D at baseline. We repeatedly measured 207 plasma known lipid metabolites at baseline and after 1 year of follow-up. We built combined factors of lipid species using principal component analysis and assessed the association between these lipid factors (or their 1-year changes) and T2D incidence. RESULTS Baseline lysophosphatidylcholines and lysophosphatidylethanolamines (lyso-phospholipids [LPs]), phosphatidylcholine-plasmalogens (PC-PLs), sphingomyelins (SMs), and cholesterol esters (CEs) were inversely associated with risk of T2D (multivariable-adjusted P for linear trend £0.001 for all). Baseline triacylglycerols (TAGs), diacylglycerols (DAGs), and phosphatidylethanolamines (PEs) were positively associated with T2D risk (multivariable-adjusted P for linear trend <0.001 for all). One-year changes in these lipids showed associations in similar directions but were not significant after adjustment for baseline levels. TAGs with odd-chain fatty acids showed inverse associations with T2D after adjusting for total TAGs. CONCLUSIONS Two plasma lipid profiles made up of different lipid classes were found to be associated with T2D in participants at high cardiovascular risk. A profile including LPs, PC-PLs, SMs, and CEs was associated with lower T2D risk. Another profile composed of TAGs, DAGs, and PEs was associated with higher T2D risk.
U2 - 10.2337/dc18-0840
DO - 10.2337/dc18-0840
M3 - Journal article
C2 - 30327364
AN - SCOPUS:85056802094
VL - 41
SP - 2617
EP - 2624
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 12
ER -
ID: 358090069